Lab trials prove copper therapy enhances cognitive function and spatial learning

Monash University researchers found that the copper-delivering drug Cu(ATSM) reduces toxic Alzheimer’s proteins and improves long-term spatial memory in laboratory experiments. According to a study published in the journal ACS Chemical Neuroscience, the compound repairs waste-clearing pumps at the blood-brain barrier, which reduced toxic amyloid-beta by 42% and improved spatial learning by nearly 44% over 56 days.

How does Cu(ATSM) clear toxic proteins from the brain?

Alzheimer’s disease is driven by the accumulation of toxic proteins known as amyloid-beta. Normally, the brain utilizes P-glycoprotein (P-gp) pumps at the blood-brain barrier to flush these proteins into the bloodstream, but these pumps weaken in Alzheimer’s patients.

View this post on Instagram about Professor Joseph Nicolazzo, Professor Nicolazzo

From Instagram — related to Professor Joseph Nicolazzo, Professor Nicolazzo

Lead author Dr. Jae Pyun of the Monash Institute of Pharmaceutical Sciences (MIPS) reported that Cu(ATSM) increased the abundance of these P-gp clearance pumps by 24.1% in an Alzheimer’s model. This repair allows the brain to clear trapped waste, which Dr. Pyun says results in behavioral benefits.

Did You Know? Alzheimer’s and other forms of dementia have recently become the leading cause of death in Australia, surpassing coronary heart disease.

Why is this copper-based treatment significant?

The ability to reduce amyloid burden is clinically proven to improve functional outcomes. Professor Joseph Nicolazzo, Director of the Centre for Drug Candidate Optimisation at MIPS, stated that these preclinical results provide a strong rationale for testing the drug in early symptomatic Alzheimer’s disease.

Alzheimer's Research at Monash Institute of Pharmaceutical Sciences

Because Cu(ATSM) has already undergone safety evaluations for other conditions, it may transition into human clinics more quickly. Professor Nicolazzo noted the compound has anti-inflammatory and neuroprotective properties and has already progressed to clinical testing for ALS and Parkinson’s.

Expert Insight: Samantha Carter notes that the use of a compound already vetted for safety in Parkinson’s and ALS trials significantly lowers the typical barrier to entry for new Alzheimer’s therapeutics. By targeting the blood-brain barrier’s mechanical failure rather than just the proteins themselves, this approach addresses a fundamental neurovascular dysfunction.

What happens next in the research?

Researchers are now working to map the exact biological routes proteins take to exit the brain. While the repair of the blood-brain barrier is confirmed, scientists suspect the copper treatment may also empower microglia—the brain’s immune cells—to consume and degrade toxic plaques.

Future studies are likely to focus on tracking these precise clearance mechanisms into the bloodstream. These findings establish a foundation for exploring further biometal therapies to combat memory loss and blood vessel dysfunction. Source: ACS Chemical Neuroscience.

Frequently Asked Questions

What is Cu(ATSM)?
It is a copper compound with neuroprotective and anti-inflammatory properties that delivers copper to the brain.

How much did the treatment improve cognitive function?
In the laboratory model, the treatment improved spatial learning by nearly 44% over a 56-day period.

Has this drug been tested in humans before?
Yes, according to Professor Joseph Nicolazzo, the compound has already progressed to clinical testing for conditions including ALS and Parkinson’s.

Do you believe biometal therapies could become a standard part of dementia care?